On November 19, 2025 TriOar reported that it has signed a technology transfer and co-development conversion rights agreement with Celltrion for its platform technology, ‘ TRACAD ( TriOar’s Conditionally Activatable Domain )’. The scale of the contract is a total of $356 million (approx. 522 billion won) if all licenses for six targets are exercised, including development milestones of up to $231 million (approx. 338 billion won) and sales milestones of up to $125 million (approx. 183 billion won).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Triore is a biotech company in the ADC sector. In short, ADCs are next-generation anticancer drugs that deliver drugs directly using a guided missile-like mechanism. They consist of a structure in which an antibody that binds to cancer antigens is combined with a cytotoxic drug (payload) capable of killing cancer cells via a linker . Because the antibody guides the drug to cancer cells and attacks them selectively, it targets only cancer cells rather than normal cells. Compared to conventional chemotherapy, this approach enhances efficacy, reduces drug toxicity, and minimizes damage to normal tissues. TROCAD, Triore’s core platform technology , is designed to ensure drugs reach cancer tissue more accurately while blocking unnecessary binding to normal cells. It maximizes drug delivery efficiency to cancer lesions while reducing toxicity by blocking binding to normal cells.

Celltrion can apply the technology to the development and commercialization of up to six ADCs . The agreement also includes an option to switch to joint development for two of these targets. If Celltrion exercises this option, the two companies will share additional ADC application technologies and know-how.

Triore emphasized, "This agreement is considered recognition of the competitiveness of our platform technology in the global market," adding, "Both companies plan to expand cooperation in new drug development based on this technology in the future."

(Press release, TriOar Biotechnology, NOV 19, 2025, View Source;idx=13 [SID1234664837])

On November 19, 2025 JSR reported First Half of Fiscal Year Ending March 31 2026 Business Status Briefing Materials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, JSR, NOV 19, 2025, View Source [SID1234661835])

On November 19, 2025 Defence Therapeutics Inc. ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), reported a major step forward in the fight against cancer that goes beyond the ADCs current limitations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following successful presentations and meetings at the World ADC Conference in San Diego with ADC companies as well as with industry leaders and pioneers at CPHI in Frankfurt, Defence is moving forward with the strategy to become a supplier of its Accum platform technology to ADC companies struggling with dosing and toxicity as well as to improve the drug delivery precision to cancer cells more effectively for the benefit of cancer patients.

"Many pharmaceuticals and biotech companies have ADCs on the market or in development. A lot of these companies are facing the same challenge, their ADC being toxic for the patients at therapeutic dose. Defence’s Accum technology can universally enhance the potency of any ADCs, reducing their toxicity, while retaining their epitope selectivity and tumor targeting" said Dr. Maxime Parisotto, Chief Scientific Officer at Defence Therapeutics.

Defence has completed studies confirming its ability to enhance ADCs potency. The most recent comparative study, in mouse xenograft models of HER2-positive breast cancer (JIMT-1 cells), demonstrated a ~20-fold higher anti-tumor efficacy with Accum-Kadcyla than Kadcyla alone when administered at the same dose (0.5 mg/kg). The tumor growth significantly halted in the Accum-Kadcyla-treated group, resulting in a consistent and near-complete response in 90% of the mice while Kadcyla alone at the same dose (0.5 mg/kg) had no effective results on inhibiting tumor growth (see November 4, 2025 press release).

Defence is engaging with ADC companies to transform the ADC cancer therapies with its unique proprietary Accum technology platform to be used with any antibodies and on any indications. Defence’s technology and team are in place to deliver the strategy and build an ADC drug delivery powerhouse.

(Press release, Defence Therapeutics, NOV 19, 2025, View Source;utm_medium=rss&utm_campaign=defence-therapeutics-to-build-adc-drug-delivery-powerhouse-using-its-proprietary-accum-technology [SID1234660863])

On November 19, 2025 Vir Biotechnology, Inc. (Nasdaq: VIR), reported that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3 at 10:50 a.m. ET / 7:50 a.m. PT in Miami, Florida.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

(Press release, Vir Biotechnology, NOV 19, 2025, View Source [SID1234660106])

On November 19, 2025 Hemispherian AS, a biotechnology company pioneering first-in-class TET2-activating therapeutics for difficult-to-treat cancers, reported that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application titled "Deoxy-Cytidine or Uridine Derivatives for Use in Cancer Therapies" (U.S. Patent Application No. 18/602,969).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent covers the use of Hemispherian’s lead clinical candidate, GLIX1, for the treatment of cancers in which cytidine deaminase (CDA) is not over-expressed beyond a defined threshold — a characteristic found in over 90% of cancers.

This allowance substantially strengthens GLIX1’s intellectual property protection until 2040 with eligibility for up to five additional years. Corresponding applications are pending internationally.

"Receiving this Notice of Allowance is an important milestone and a major validation of GLIX1’s potential," said Zeno Albisser, Chief Executive Officer of Hemispherian. "This patent protects the ability to explore GLIX1 across the vast majority of cancers together with our partner BioLineRx Ltd. (NASDAQ: BLRX). As we advance toward first-in-human studies in glioblastoma, this strengthened IP position enables us to accelerate parallel development strategies in additional tumor types."

GLIX1 is a first-in-class, orally available small molecule designed to modulate the DNA damage response by selectively activating TET2. The molecule has demonstrated potent anti-cancer activity in multiple preclinical models.

A Strengthened Global Patent Estate for GLIX1

The newly allowed U.S. patent expands the extensive international IP portfolio for GLIX1:

GLIX1 for the treatment of cancers of the central nervous system, including glioblastoma, is protected by issued patents in the U.S., Europe, and 13 additional countries. These patents extend to at least 2040 (with potential extension).
GLIX1 in combination with PARP inhibitors for the treatment of homologous recombination (HR)-proficient cancers is protected under a pending international patent application. If granted, national-phase patents will provide protection through 2044, with possible extensions.
Advancing Toward First-in-Human Trials

Hemispherian’s joint venture with BioLineRx is preparing to initiate a Phase 1/2a clinical trial of GLIX1 in glioblastoma in Q1 2026. In parallel, the joint venture continues to advance preclinical studies in additional solid tumor types enabled by this broadened IP protection.

(Press release, Hemispherian, NOV 19, 2025, View Source [SID1234660105])